Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
Bullish Continuation in '24? 3 Market Areas to Watch
Cramer names biopharma companies to watch as industry mergers start to pile up
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
Yes Virginia, There Is a Santa Claus Rally
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
Nano Dimension Buys Stratasys, Bristol Myers's Shopping Spree, Apple Gets a ‘No'
Bristol-Myers buying Karuna signals a biotech boom ahead: Jefferies
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc.
Bristol Myers Squibb buys neurological drug developer Karuna Therapeutics in $14B deal
Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook
Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal
Biotech stocks set for a rebound in 2024, analysts say
Shareholder Alert: Ademi LLP investigates whether Karuna Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol-Myers
Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal
A Major Acquisition and Other News Ahead of the Holiday Weekend
Karuna Stock Soars On Bristol Myers' $14 Billion Takeover
Bristol Myers to buy Karuna Therapeutics for $14B
KRTX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Karuna Therapeutics, Inc. Is Fair to Shareholders
Bristol Myers to Buys Karuna Therapeutics in $14 Billion Pharma Deal: Report
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Karuna Therapeutics' stock rockets into record territory after report Bristol Myers' $14 billion buyout agreement
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia
FDA Accepts Karuna's (KRTX) NDA Filing for Schizophrenia Drug
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
Karuna (KRTX) Posts Upbeat Safety Data on Schizophrenia Drug
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine
Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript
Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss
Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress
Karuna Therapeutics to Present at Upcoming Investor Conferences
Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023
Karuna Therapeutics: KarXT Could Become A New Standard Of Care In Schizophrenia
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress
Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug
Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia
Karuna Therapeutics to Present at Upcoming Investor Conferences
Karuna: NDA Filing Q3 Of 2023 And Expanded Potential With KarXT
Karuna's Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade)
Karuna Therapeutics, Inc. (KRTX) Q2 2023 Earnings Call Transcript
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q2
Karuna Therapeutics, Inc. (KRTX) Reports Q2 Loss, Lags Revenue Estimates
Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates